Skip to main content

Table 4 Baseline concomitant medications used by ≥10% of adult patientsa

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Medication, n (%)b rhPTH(1-84)
(n=125)
Conventional therapy
(n=571)
Analysis populationc
(N=696)
Vitamin D and analogs 105 (84.0) 523 (91.6) 628 (90.2)
 Calcitriol 86 (68.8) 430 (75.3) 516 (74.1)
 Native vitamin D, including cholecalciferol and ergocalciferol 75 (60.0) 255 (44.7) 330 (47.4)
 Alfacalcidol 1 (0.8) 55 (9.6) 56 (8.0)
Calcium 96 (76.8) 466 (81.6) 562 (80.7)
 Calcium carbonate 62 (49.6) 333 (58.3) 395 (56.8)
 Calcium citrate 46 (36.8) 148 (25.9) 194 (27.9)
 Calcium, not otherwise specified 9 (7.2) 39 (6.8) 48 (6.9)
Thyroid hormone 86 (68.8) 424 (74.3) 510 (73.3)
 Levothyroxine 79 (63.2) 417 (73.0) 496 (71.3)
Magnesium 46 (36.8) 140 (24.5) 186 (26.7)
Proton pump inhibitors 26 (20.8) 127 (22.2) 153 (22.0)
Benzodiazepine derivatives 26 (20.8) 74 (13.0) 100 (14.4)
HMG-CoA reductase inhibitors 16 (12.8) 115 (20.1) 131 (18.8)
Potassium 25 (20.0) 66 (11.6) 91 (13.1)
Combinations of vitamins 23 (18.4) 91 (15.9) 114 (16.4)
Antidepressants 23 (18.4) 56 (9.8) 79 (11.4)
Selective serotonin reuptake inhibitors 22 (17.6) 70 (12.3) 92 (13.2)
Platelet aggregation inhibitorsd 10 (8.0) 92 (16.1) 102 (14.7)
Glucocorticoids 17 (13.6) 91 (15.9) 108 (15.5)
Thiazides, hydrochlorothiazide 16 (12.8) 76 (13.3) 92 (13.2)
Beta-blocking agents, selective 15 (12.0) 67 (11.7) 82 (11.8)
  1. HMG-CoA reductase 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aDrug class cutoff based on analysis population
  3. bMedication coded using the World Health Organization Drug Dictionary
  4. cBaseline is defined as the assessment at enrollment (visit 1); pediatric patients (n=27) and those who received rhPTH(1-34) (n=14) were excluded from the analysis
  5. dExcludes heparin